Experimental Studies on a Recombinant Hirudin, CGP 39393

Summary

The in vitro anticoagulant activities of recombinant desulphatohirudin (r-hirudin) were studied in the activated partial thromboplastin time (APTT) and the thrombin generation test : systems. In the APTT at concentrations below 5 μg/ml, r-hirudin showed a dose-response curye. At concentrations above 5 μg/ml, the plasma became unclottable, but in the thrombin generation test , at least 10 μg/ml of r-hirudin was required for full inhibition of thrombin generation. The antithrombotic effect was assessed using a rabbit venous stasis model; 150 μg/ml r-hirudin completely prevented thrombus formation at 10 and 20 min stasis. At antithrombotic dose, the mean bleeding time ratio measured in a rabbit ear template model, was not prolonged over control values. At higher doses, the bleeding time ratios were higher than those observed for the same dosage of heparin. These data indicate that while r-hirudin is an effective antithrombotic agent, antithrombotic doses have to be carefully titrated to avoid excessive bleeding.

• References

• 1 Markwardt F. Die antagonistische Wirkung des Hirudins gegen Thrombin in vivo. Naturwissenschaften 1956; 43: 111
• 2 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe Seylers Z Physiol Chem 1957; 308: 147-156
• 3 Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemostas 1989; 15: 269-282
• 4 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628
• 5 Meyhack B, Hinnetr A, Heim J. Heterologous gene expression in saccharomyces cerivisiae. In: Genetics and Molecular Biology of Industrial Microorganisms Hershberger CL, Queener SW, Hegeman G. eds Amercian Society for Microbiology; Washington DC: 1989: 311-321
• 6 Fortkamp E, Rieger M, Heisterberg-Moutses G, Schweitzer S, Sommer R. Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. DNA 1986; 5: 511-517
• 7 Bergman C, Dodt I, Kohler S, Fink E, Gassen HG. Chemical synthesis and expression of a gene coding for hirudin, the thrombin specific inhibitor from the leech Hirudo medicinalis. Biol Chem Hoppe Seyler 1986; 367: 731-740
• 8 Harvey RP, Degryse E, Stefani L, Schamber R, Cazenave JR, Courtney M, Tolstoshev P, Lecocq JP. Cloning and expression of a CDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci USA 1986; 83: 1084-1088
• 9 Thlbot MD, Ambler J, Bulter KD, Findlay VS, Mitchell KA, Peters RR, Tweed MR, Wallis RB. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemostas 1989; 6l: 77-80
• 10 Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemostas 1990; 63: 204-207
• 11 Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walengs J, Fareed E. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. Thromb Res 1989; 54: 435-445
• 12 Hemker HC, Beguin S, Pieters J, Lindhout T. The ex vivo correlate of the antithrombotic action of heparin. Ann NY Acad Sci 1989; 556: 146-157
• 13 Thomas DR, Merton RE, Gray E, Barrowcliffe TW. The relative antithrombotic effectiveness of heparin, of a low molecular weightheparin, and a pentasaccharide fragment in an animal model. Thromb Haemostas 1989; 61: 204-7
• 14 Thomas DR, Merton RE, Barrowcliffe TW. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs. Ann NY Acad Sci 1989; 556: 313-322
• 15 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis inducing ability in human serum. J Appl Physiol 1959; 14: 943-946
• 16 Walenga JM, Pifarre R, Hoppensteadt DA, Fareed J. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations. Semin Thromb Hemostas 1989; 15: 316-344
• 17 Banowcliffe N, Thomas DP. Anticoagulant activities of heparin and fragments. Ann NY Acad Sci 1989; 556: 132-145
• 18 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-842
• 19 Barrowcliffe TW, Gray E. Studies of phospholipid reagents used in coagulation II: factors influencing their sensitivity to heparin. Thromb Haemostas 1981; 46: 634-637
• 20 Gray E, Watton J, Barrowcliffe TW. Comparison of heparin, hirudin and dermatan sulphate - effects on thrombin activation of factor VIII. Br J Haematol Spec Suppl 1989 14.
• 21 Ofosu FA, Sie R, Modi GJ, Fernandez R, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive feedback reactions is critical to the suppression of the anticoagulant effect of heparin. Biochem J 1987; 243: 579-588
• 22 Bdguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1988; 60: 457-462
• 23 Hawkey CM. Comparative Mammalian Haematology. Cellular Components and Blood Coagulation of Captive Wild Animals. Pub William Heinemann Medical Books Ltd, London 1975
• 24 Freund M, Cazenave JR, Courtney M, Degryse E, Roitsch C, Bernat A, Delebassde D, Defreyn G, Maffrand JP. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemostas 1990; 63: 187-192
• 25 Kaiser B, Markwardt E. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res 1986; 43: 613-620
• 26 Markwardt I, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-388
• 27 Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74 (03) 1021-1024